Log in

Relevant bibliographies by topics / (") san yan er pai (")

Contents

Journal articles
Dissertations / Theses
Books
Conference papers

Academic literature on the topic '(") san yan er pai (")'

Author: Grafiati

Published: 27 February 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic '(") san yan er pai (").'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "(") san yan er pai (")"

1

백철. "Commercial Consciousness of San yan er pai." Journal of Chinese Language and Literature ll, no. 75 (June 2016): 251–75. http://dx.doi.org/10.26586/chls.2016..75.010.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Ham, Eun Sun. "Analysis on the Behavior Motivation of the Matchmakers in “San yan” and “Er pai”." Journal of Chinese Studies 86 (November 30, 2018): 61–77. http://dx.doi.org/10.35982/jcs.86.3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

SoJung kim. "The two different perspectives on Women, a male narrative in San-Yan(三言) & Er-Pai(二拍) & Huan-Xi-Yyuan-Jia(歡喜寃家)." Journal of the research of chinese novels ll, no. 28 (September 2008): 215–36. http://dx.doi.org/10.17004/jrcn.2008..28.012.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Ouyang, Quchang, Huihua Xiong, Min Yan, Jincai Zhong, Li Ran, Ting Luo, Liping Liu, et al. "Abstract P2-13-32: Pyrotinib in combination with letrozole for estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: A multicenter, single-arm, phase II trial." Cancer Research 82, no. 4_Supplement (February 15, 2022): P2–13–32—P2–13–32. http://dx.doi.org/10.1158/1538-7445.sabcs21-p2-13-32.

Full text

Abstract:

Abstract Background: HER2-targeted agents combined with endocrine therapy (ET) has been recommended as an optional therapeutic strategy for hormone receptor (HR)/human epidermal growth factor receptor 2 (HER2) co-positive metastatic breast cancer (MBC). Pyrotinib is an oral irreversible pan-ErbB receptor tyrosine kinase inhibitor targeting EGFR, HER2 and HER4, with proven efficacy in combination with chemotherapy in HER2-positive MBC. This multicenter, single-arm phase 2 trial aimed to investigate the efficacy and safety of pyrotinib plus letrozole in patients with estrogen receptor (ER)-positive, HER2-positive MBC (NCT04407988). Methods: Pre-/perimenopausal or postmenopausal women with histologically confirmed HER2-positive (immunohistochemistry [IHC] 3+ or 2+ with fluorescence in situ hybridization positive) and ER-positive (the percentage of ER+ cells ≥ 10% by IHC) MBC were enrolled. Prior treatment for metastatic disease was not allowed. Eligible patients received pyrotinib (400 mg, po, qd) plus letrozole (2.5 mg, po, qd) until disease progression or unacceptable toxicity. For pre-/perimenopausal patients, additional treatment with ovarian function suppression (OFS) was required. The primary endpoint was clinical benefit rate (CBR), defined as the rate of patients with complete response (CR), partial response (PR), or stable disease (SD) for at least 24 weeks per RECIST 1.1. Secondary endpoints included objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and safety. Results: Between December 3, 2019 and April 2, 2021, 26 patients were enrolled. As of July 5, 2021, CBR was 76.9% (20 of 26; 95% CI 56.4% to 91.0%) and ORR was 57.7% (15 of 26; 95% CI 36.9% to 76.6%). One of the 26 patients (3.8%) had CR, 14 (53.8%) had PR, 5 (19.2%) had SD, 5 (19.2%) had progressive disease, and 1 (3.8%) had not evaluable disease. The benefits in CBR and ORR were observed across all subgroups. The most common any grade AEs were diarrhea (25 of 26, 96.2%), vomiting (8 of 26, 30.8%), nausea (6 of 26, 23.1%), and oral ulceration (6 of 26, 23.1%). Diarrhea was the only reported grade 3 AE that occurred in 5 patients (19.2%). No grade 4 or 5 AEs occurred during this study. Conclusions: Pyrotinib combined with letrozole showed an encouraging antitumor activity with good tolerance in patients with ER/HER2 co-positive MBC, promising as an alternative treatment option for this disease. The study is ongoing. Citation Format: Quchang Ouyang, Huihua Xiong, Min Yan, Jincai Zhong, Li Ran, Ting Luo, Liping Liu, Jing Li, Xiaohong Yang, Huawu Xiao, Ning Xie, Hui Wu, Jianxiang Gao, Jun Lu, Xuming Hu, Zheyu Hu, Can Tian, Zhengrong Shui, Min Cao. Pyrotinib in combination with letrozole for estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: A multicenter, single-arm, phase II trial [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P2-13-32.

APA, Harvard, Vancouver, ISO, and other styles

5

Tseng, Chu-Yao, Ching-Wen Huang, Hsin-Chia Huang, and Wei-Chen Tseng. "Utilization Pattern of Traditional Chinese Medicine among Fracture Patients: A Taiwan Hospital-Based Cross-Sectional Study." Evidence-Based Complementary and Alternative Medicine 2018 (September 30, 2018): 1–9. http://dx.doi.org/10.1155/2018/1706517.

Full text

Abstract:

Traditional Chinese medicine (TCM) divides fracture treatment into three stages. Many TCM herbs and formulas have been used to treat fractures for thousands of years. However, research regarding the Chinese herbal products (CHPs) that should be used at different periods of treatment is still lacking. This study aims to identify the CHPs that should be used at different periods of treatment as well as confirm the TCM theory of fracture periods medicine. We used prescriptions of TCM outpatients with fracture diagnoses analyzed using the Chang Gung Research Database (CGRD) from 2000 to 2015. According to the number of days between the date of the fracture and the clinic visit date, all patients were assigned to one of three groups. Patients with a date gap of 0-13 days were assigned to the early period group; those with a date gap of 14-82 days were assigned to the middle period group; and those with a date gap of 83-182 days were assigned to the late period group. We observed the average number of herbal formulas prescribed by the TCM doctor at each visit was 2.78, and the average number of single herbs prescribed was 6.47. The top three prescriptions in the early fracture period were Zheng-gu-zi-jin-dang, Shu-jing-huo-xue-tang, and Wu-ling-san. In the middle fracture period, the top three formulas were Zheng-gu-zi-jin-dang, Shu-jing-huo-xue-tang, and Zhi-bai-di-huang-wan. In the late fracture period, the top three formulas were Shu-jing-huo-xue-tang, Gui-lu-er-xian-jiao, and Du-huo-ji-sheng-tang. The main single herbs used in the early fracture period were Yan-hu-suo, Gu-sui-bu, and Dan-shen. From the middle to the late period, the most prescribed single herbs were Xu-duan, Gu-sui-bu, and Yan-hu-suo. We concluded that the results showed that the CGRD utilization pattern roughly meets the TCM theory at different fracture periods.

APA, Harvard, Vancouver, ISO, and other styles

6

Oshi, Masanori, Shipra Gandhi, Yoshihisa Tokumaru, Rongrong Wu, Li Yan, Akimitsu Yamada, Takashi Ishikawa, Itaru Endo, and Kazuaki Takabe. "Abstract P5-03-01: Conflicting roles of EGFR expression by subtypes in breast cancer." Cancer Research 82, no. 4_Supplement (February 15, 2022): P5–03–01—P5–03–01. http://dx.doi.org/10.1158/1538-7445.sabcs21-p5-03-01.

Full text

Abstract:

Abstract Epidermal growth factor receptor (EGFR) is one of the receptors that belongs to the epidermal growth factor family of receptor tyrosine kinases (ErbBs). Several malignancies including breast cancer that express EGFR have poor prognosis. Our study examined the EGFR expression among 5176 breast cancer patients from multiple independent breast cancer cohorts and its contribution to tumor immune microenvironment in different subtypes. We found that, EGFR expression in triple negative breast cancer (TNBC) was the highest among breast cancer subtypes in GSE96058 and METABRIC cohorts when compared to other subtypes (both p < 0.001), which is in agreement with the existing literature. High EGFR expression was significantly associated with improved survival in ER-positive/HER2-negative breast cancer in both cohorts (both p < 0.001) and also significantly associated with high level of intratumor heterogeneity and homologous recombination deficits (HRD) (both p < 0.001) in the TCGA cohort. Furthermore, high EGFR expression tumor enriched not only several pro-cancer-related gene sets, but also immune-related gene sets, including Allograft rejection, inflammatory response, IL2/STAT5 signaling, IL6/JAK/STAT3 signaling, coagulation and complement pathway in both cohorts. On the other hand, low EGFR tumor enriched cell proliferation-related gene sets, including E2F targets, G2M checkpoint MYC targets v1 and v2, and DNA repair, which may explain the observed worse survival (all normal enrichment score < -0.50). However, these findings were not observed in TNBC. Interestingly, high EGFR ER-positive/HER2-negative breast cancers were infiltrated with anti-cancer immune cells (CD8+ T cell, CD4+ T cell, and dendritic cell), and associated with high level of cytolytic activity (CYT) (p < 0.001). On the other hand, a lower fraction of immune cells was observed in high EGFR TNBC along with low level of CYT (p < 0.001). In the single cell sequence data, tumor cells have significantly higher EGFR expression compared to immune cells (p < 0.001). High EGFR expression among ER-positive/HER2-negative breast cancer was significantly associated with higher expression of immune checkpoint molecules (PD-1, PD-L1 and PD-L2, CTLA4, IDO1, and BTLA; all p < 0.001), while, on the other hand, there was lower immune checkpoint molecule expression in high EGFR TNBC. Finally, high EGFR metastatic tumor was associated with worse survival, but there was no association with infiltrating immune cells. In conclusion, EGFR expression was found to have different characteristics depending on breast cancer subtype. Especially, high EGFR ER-positive/HER2-negative breast cancer was significantly associated with better survival and immunity in tumor immune microenvironment. Citation Format: Masanori Oshi, Shipra Gandhi, Yoshihisa Tokumaru, Rongrong Wu, Li Yan, Akimitsu Yamada, Takashi Ishikawa, Itaru Endo, Kazuaki Takabe. Conflicting roles of EGFR expression by subtypes in breast cancer [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P5-03-01.

APA, Harvard, Vancouver, ISO, and other styles

7

Oshi, Masanori, Rongrong Wu, Akimitsu Yamada, Li Yan, Takashi Ishikawa, Itaru Endo, and Kazuaki Takabe. "Abstract P4-07-29: Reactive Oxygen Species (ROS) pathway is associated with aggressive cancer biology, elevated immune response, and with worse survival in ER-positive/HER2-negative breast cancer." Cancer Research 82, no. 4_Supplement (February 15, 2022): P4–07–29—P4–07–29. http://dx.doi.org/10.1158/1538-7445.sabcs21-p4-07-29.

Full text

Abstract:

Abstract Background: Reactive oxygen species (ROS) in tumor microenvironment are known to promote many aspects of cancer progression. On the other hand, excessive accumulation of ROS can induce cancer cell apoptosis. To our knowledge, clinical relevance of ROS response signaling in breast cancer has never been studied in multiple large patient cohorts. Here, we hypothesized that the high ROS pathway score reflect tumor aggressiveness, thus, it predicts worse survival in breast cancer patients. Methods: A total of 6245 breast cancer patients from three independent cohorts (GSE96058, METABRIC, and TCGA) were analyzed. We defined the ROS pathway score by the degree of enrichment by Gene Set Variant Analysis (GSVA) and median was used to divide high vs low score groups in each cohort. Results: The ROS score was significantly associated with aggressive clinical factors, such as triple-negative breast cancer (TNBC) subtype, Nottingham histological grade, American Joint Committee on Cancer (AJCC) Stage and lymph node metastasis consistently in both GSE96058 and METABRIC (all p < 0.001). High ROS score was significantly associated with worse overall survival (OS) in the GSE96058 (hazard ratio (HR) = 3.59, 95% confidence interval (CI); 2.47-5.20, p < 0.001), as well as OS (HR = 1.55, 95%CI; 1.16-2.07, p = 0.002), disease-free survival (HR = 1.63, 95%CI; 1.10-2.43, p = 0.016), and disease-specific survival (HR = 2.57, 95%CI; 1.75-3.77, p < 0.001) in the METABRIC cohort. Subgroup analysis revealed that a high ROS score was significantly associated with worse OS in ER-positive/HER2-negative breast cancer in both cohorts. High ROS ER-positive/HER2-negative breast cancer was significantly associated with high level of intratumor heterogeneity (p = 0.013), homologous recombination deficient (HRD) (p < 0.001), and mutation-related score (silent and non-silent mutation rate (p = 0.003 and 0.011, respectively), fraction altered (p = 0.038), and single-nucleotide variant (SNV) neoantigens (p = 0.006)) in the TCGA cohort. In agreement, high ROS ER-positive/HER2-negative breast cancer significantly enriched cell proliferation-related gene sets; E2F targets, G2M checkpoint, and MYC targets v1 and v2 consistently in both GSE96058 and METABRIC cohorts (all false discovery rate (FDR) < 0.25). On the other hand, high ROS ER-positive/HER2-negative tumors were associated with elevated infiltration of multiple immune cells, including anti-cancer immune cells (CD8+ T cell, CD4+ memory T cell, M1 macrophage, dendritic cell, gamma-delta T cell), as well as pro-cancer immune cells (regulatory T cell, T helper type2 cell, and M2 macrophage) and with high level of cytolytic activity (CYT) consistently in both cohorts (all p < 0.001). Those tumors also enriched immune-related pathway (Interferon (IFN)-α response, IFN-γ response, allograft rejection, complement, IL6/JAK/STAT3 signaling, and inflammatory response) consistently in both cohorts (all FDR < 0.25). Finally, high ROS ER-positive/HER2-negative breast cancer was significantly associated with high expression of immune checkpoint molecules including PD-1, PD-L1 and PD-L2, CTLA4, IDO1, LAG3, BTLA, HLA-A, and TIGIT, in (all p < 0.005). Conclusion ROS pathway is associated with cancer aggressiveness, elevated immune response, and with worse survival in ER-positive/HER2-negative breast cancer. Citation Format: Masanori Oshi, Rongrong Wu, Akimitsu Yamada, Li Yan, Takashi Ishikawa, Itaru Endo, Kazuaki Takabe. Reactive Oxygen Species (ROS) pathway is associated with aggressive cancer biology, elevated immune response, and with worse survival in ER-positive/HER2-negative breast cancer [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P4-07-29.

APA, Harvard, Vancouver, ISO, and other styles

8

LEE, Wing-yi. "明代婦女自殺——倫理學研究的進路." International Journal of Chinese & Comparative Philosophy of Medicine 3, no. 2 (January 1, 2001): 77–119. http://dx.doi.org/10.24112/ijccpm.31399.

Full text

Abstract:

LANGUAGE NOTE | Document text in Chinese; abstract also in English.現代人對於自殺的討論，普遍地從科學的觀點剖析，視之為與疾病有關。從科學的觀點而言，當事人是在受制於心理或生理的疾病影響下作出自殺的行為。他們的自殺，是處於“不由自主”、“無力選擇”下的自殺，當事人其實是“受害者”，需要的是心理輔導、醫治以預防自殺，而非對其背後所包含的價值觀予以討論。然而，有一些自殺卻不能歸納為與疾病有關。當事人的自殺，是處於自主的狀態之中，是經過深思熟慮，有其充分道德理據下的自主行為。當事人自殺的理據，是與同時代，同一社群的人所認同的道德價值觀，有著密切的關係。對當事人的自殺子以道德價值上的探討，則屬於倫理學上的討論。本文以明代的婦女自殺為例，試從倫理學研究的進路，探究古代中國人的自殺。Modern people usually discuss suicide from scientific views and treat it as a kind of disease. Suicidal behavior occurs under the influence of psychological or physiological illness; it is an involuntary behavior. People who commit suicide are deemed the "victims" of their illnesses. All what we should do is to prevent, to intervene and to postvent their suicidal behavior.However, some cases of suicide are not due to illness. They are the result of voluntary and deliberate moral choice. The reasons of committing suicide are associated with the ethical values of people in the same period of time and in the same community. For example, the moral principle of "zhen" played an important role in woman suicide of Ming Dynasty. In Ming Dynasty, " zhen" was manifested in three ways: (1) "Congi er yongzhong", women should commit suicide after the death of their husbands in order to express loyalty. (2) "Daili er zhengshi", women should commit suicide if they have inappropriate sexual relations with other people, such as pre-marital sex, in order to express their regret and to cover up their sinful behavior. (3) "Sijie", women should commit suicide in order to avoid being raped.Although the government and some intellectuals in Ming Dynasty encouraged women to commit suicide for "men", the suicide and suicide attempt cases in San Yan show that women should consider other moral principles and other values of life and death before they commit suicide. We found that the moral principle of "xiao" overrode the moral principle of "men" in some cases of woman suicide and suicide attempt in San Yan. In Chinese society, "xiao" was manifested in three ways: (l) "Fengyang shuangqin", women should keep their lives for supporting and serving their parents. (2) "Fengyang sizi", women should keep their lives for bringing up their children. (3) "Wei Jiaren Baochou", women should keep their lives for avenging their dead family members. Under the moral principle of "xiao", women should give up suicide. The purpose of this paper is to uncover the underlying values of woman suicide in Ming Dynasty and give an ethical analysis on it.DOWNLOAD HISTORY | This article has been downloaded 68 times in Digital Commons before migrating into this platform.

APA, Harvard, Vancouver, ISO, and other styles

9

Chen, Grace, Stacy W. Blain, Irina Jilishitz, Allison Vanlnwegen, Lingyue Yan, and Yun Wu. "Abstract P5-16-18: Developing IpY: A novel inhibitor for the treatment of ER+ CDK4i-resistant breast cancer." Cancer Research 82, no. 4_Supplement (February 15, 2022): P5–16–18—P5–16–18. http://dx.doi.org/10.1158/1538-7445.sabcs21-p5-16-18.

Full text

Abstract:

Abstract Almost 270,000 US women will be diagnosed with breast cancer (BC) this year, anddespite advances in treatment, ~40,000 women will die. ER/PR+ (endocrineresponsive), Her2- tumors occur in approximately 40% of breast cancer patients andare candidates for drugs targeting estrogen responsiveness, such as letrozole orfulvestrant. CDK4 targeting drugs (CDK4i) like palbociclib, abemaciclib, or ribociclib arenow approved in combination with letrozole or fulvestrant as a front- and second-linetherapy for metastatic ER/PR+, Her2- patients. However, while combined ER andCDK4i treatment significantly extends Progression Free Survival (PFS), those treatedinvariably develop resistance. Thus, drug resistance remains an urgent unmet need, as current treatments only marginally improve Overall Survival (OS) for these patients.Resistance to palbociclib develops because of compensation by another kinase, CDK2, suggesting that to be effective, therapies must be developed to inhibit both CDK4 andCDK2. Concarlo has taken a different approach to inhibit CDK4 and CDK2 by targetingp27Kip1 (p27). p27 interacts specifically with CDK4/6 and CDK2, and is responsible forturning these kinases ON and OFF. This transition from ON to OFF is mediated by aspecific modification to p27 itself, by the tyrosine kinase BRK (breast tumor relatedkinase). Published work has shown that a naturally occurring ALTernatively splicedform of BRK, ALT, can bind to p27, blocking BRK's association, and preventing BRK'sphosphorylation of p27. This locks CDK4 and CDK2 into the OFF conformation andsimultaneously inhibits activities of both kinases. As the naked 144 aa ALT peptidedoes not enter cells, it was formulated within a lipid nano-particle (NP), and called IpY.1.IpY.1 inhibits proliferation of HR+ and triple negative (TN) BC cells, but not non-cancerous breast cells MCF10A. IpY.1 arrests CDK4i-resistant and endocrine-resistantBC cells and it is both cytostatic and cytotoxic, demonstrating that p27 is a viabletherapeutic target to combat drug resistance. In vivo, IpY reduces tumor volumes and increase OS in cell line-derived xenografts (CDX). In order to convert manufacturing of the therapeutic peptide portion of IpY from recombinant to synthetic production, Concarlo truncated the large ALT peptide and bioengineered it to a more stable form. IpY.20 has a comparable IC50 as IpY.1 in HR+and TNBC cells and does not cause growth arrest in non-cancerous MCF10A cells. Using the fluorescent-labeled variant of IpY.20 (fluo-IpY.20) injected into tumor-bearingsyngeneic CDX model, followed by IVIS imaging, we could detect fluo-IpY.20 in tumorsas early as 15 min and up to 24h post injection. 6-10% of the total fluorescent signal isallocated to tumor at all timepoints. In addition, fluo-IpY.20 inhibits the activation of itstarget in tumors within 24h, suggesting fluo-IpY.20 not only reaches tumors but alsoengages with its target. IpY.20 induces tumor regression in CDX models and animmunocompetent genetically engineered model that overexpresses the potent Erbb2oncogene. Overall, repeated dosing of IpY.20 does not exhibit significant adverseeffects and is well tolerated in immunocompetent mice. However, in these treated mice, there was an increase in platelets and production of some cytokines compared to vehicle-treated mice, suggesting that an immune response may have been initiated. By targeting p27 instead of the conserved CDK4 or CDK2 active sites, IpY.20 will bemore selective and have fewer off-target effects than the ATP-competitive smallmolecule CDK4is currently in use. As the majority of the drug resistance seen withCDK4 inhibitory drugs is a result of compensatory CDK2 activity, IpY.20 preventsacquired drug resistance by hitting both CDK4 and CDK2 simultaneously, resulting in amore durable response to the drug. Concarlo is currently in manufacturing with IpY.20. Citation Format: Grace Chen, Stacy W Blain, Irina Jilishitz, Allison Vanlnwegen, Lingyue Yan, Yun Wu. Developing IpY: A novel inhibitor for the treatment of ER+ CDK4i-resistant breast cancer [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P5-16-18.

APA, Harvard, Vancouver, ISO, and other styles

10

Oshi, Masanori, Shipra Gandhi, Michelle R. Huyser, Yoshihisa Tokumaru, Li Yan, Rongrong Wu, Akimitsu Yamada, Itaru Endo, and Kazuaki Takabe. "Abstract P1-08-17: Melk expression is associated with immune cell infiltration and pathological compete response (pcr) after neoadjuvant chemotherapy in breast cancer." Cancer Research 82, no. 4_Supplement (February 15, 2022): P1–08–17—P1–08–17. http://dx.doi.org/10.1158/1538-7445.sabcs21-p1-08-17.

Full text

Abstract:

Abstract In experimental settings, maternal embryonic leucine zipper kinase (MELK), an apical member of the snf1/AMPK serine-threonine kinases family, is highly expressed in several malignancies, and plays a role in cell cycle and proliferation in cell culture settings. However, there is no clear insight on the underlying mechanism or association of MELK expression with several key players in the tumor microenvironment (TME) in regulating cancer progression and response to several drugs in the human tumor. We investigated the clinical relevance of MELK expression by performing silico analyses of 7,135 breast cancer patients using multiple independent large cohorts in this study. We found that MELK expression was significantly correlated with tumor growth assessed by American Joint Committee Cancer (AJCC) stage (p < 0.001), Nottingham histological grade (both p < 0.001), MKI67 expression (spearman rank correlation (r) = 0.704 and 0.888, respectively, both p < 0.001), triple-negative breast cancer (TNBC) subtype (both p < 0.001) and also with cell proliferation-related gene sets (all normalized enrichment score (NES) > 1.70, all false discovery rate (FDR) < 0.01) using gene set enrichment analysis (GSEA), in two large cohorts METABRIC and GSE96058. Furthermore, we observed worse patient survival (both p < 0.001), high mutation rate (all p < 0.03), and enhanced cancer cell survival pathways, including MTORC1 signaling, DNA repair and unfolded protein response (all NES > 1.50) in high MELK expression breast cancer. Additionally, breast cancer with high MELK expression was significantly enriched in immune-related gene sets, including allograft rejection, interferon (IFN)-α response and IFN-γ response (all NES > 1.30). Furthermore, infiltration of anti-cancer immune cells (CD4+ memory T cells, T helper type1 cells, CD8+ T cells, M1 macrophages, gamma-delta T cells, and dendritic cells) and pro-cancer (T helper type 2 cells and regulatory T cells), calculated by xCell algorithm, was associated with high MELK expression. High immune cell killing activity (CYT) was also significantly associated with high MELK expression. Although MELK expression did not correlate with sensitivity of any drug tested in cell lines, high MELK was significantly associated with high pathological complete response (pCR) rate after neoadjuvant chemotherapy (NAC) not only in TNBC (area under the curve (AUC) = 0.78, 0.81, and 0.93, respectively), the aggressive breast cancer subtype known to be associated with around 30-40% pCR, but also in ER-positive plus HER2-negative breast cancer (AUC = 0.62, 0.75, and 0.80, respectively), a subtype of breast cancer where pCR rates are very low, in three cohorts GSE25066, GSE20194 and HESS cohorts. In conclusion, our study shows that high MELK expression is significantly associated with cell proliferation, immune cell infiltration, and higher incidence of response to NAC both in ER-positive/HER2-negative and TNBC. Citation Format: Masanori Oshi, Shipra Gandhi, Michelle R Huyser, Yoshihisa Tokumaru, Li Yan, Rongrong Wu, Akimitsu Yamada, Itaru Endo, Kazuaki Takabe. Melk expression is associated with immune cell infiltration and pathological compete response (pcr) after neoadjuvant chemotherapy in breast cancer [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P1-08-17.

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "(") san yan er pai (")"

1

Tsoi, Mei-lan. "A study of Fang Xiao-ru, 1357-1402 Fang Xiaoru (yi san wen yi san wu qi zhi yi si ling er) yan jiu /." Click to view the E-thesis via HKUTO, 1993. http://sunzi.lib.hku.hk/hkuto/record/B31950450.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Tung, Kwok-leung Augustus. "A study of the relationships between Chen Jitang and the Nanking Government, 1929-1936 Chen Jitang yu Nanjing zheng fu guan xi yan jiu, yi jiu er jiu zhi yi jiu san liu /." Click to view the E-thesis via HKUTO, 1991. http://sunzi.lib.hku.hk/hkuto/record/B31950085.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Chen, Ying-Chi, and 陳頴吉. "Study of “Confucian Merchants” in Ming Dynasty Novels－Based on San Yan and Er Pai." Thesis, 2010. http://ndltd.ncl.edu.tw/handle/47293685053380415986.

Full text

Abstract:

碩士
雲林科技大學
漢學資料整理研究所碩士班
98
In mid-Ming Dynasty, “Confucian merchants” became a noteworthy social phenomenon. On one hand, Confucianists bring Confucian concepts into commerce, and on the other, after merchants become economically established, they also seek to practice Confucianism, joining the ranks of scholars. In this way, the new class of “Confucian merchants” rose. These “Confucian merchants” follow traditional Confucian ethics in their business practices, finding a perfect balance between righteousness and profit, bringing a new aspect to the advanced economy of the Ming Dynasty. Feng Menglong and Lin Meng-chu were born in late Ming. As Confucian scholars, they were well-studied and held ambitions to take care of the world and its people, but were unable to realize their ambitions; they were only able to devote themselves to their literary works, San Yan and Er Pai. Therefore, this paper begins with the formative years of the authors and backgrounds of the books to discuss the real societal conditions of “Confucian merchants,” to discuss the background of “Confucian merchants” from a literary standpoint to analyze the core Confucian ethical values of “Confucian merchants” in San Yan and Er Pai. This study seeks to discover whether contemporary literary works San Yan and Er Pai concretely reflect the various phenomena in the group of “Confucian merchants,” and to reveal the extraordinary literary value of San Yan and Er Pai.

APA, Harvard, Vancouver, ISO, and other styles

4

Wang, Hen-pei, and 王瀚珮. "A Study of the Images of “ San Ku Liu Po ” in the Books “San Yan” and “Er Pai”and “E Sin”." Thesis, 2009. http://ndltd.ncl.edu.tw/handle/48637076296486504596.

Full text

Abstract:

碩士
國立臺南大學
國語文學系中國文學碩士在職專班
97
The Books “San Yan” and “Er Pai”and “ Xing Shi Yan”,which have high value in arts, are famous Chinese short stories in Ming Dynasty. The phrase “ San Ku Liu Po ” ,which means the women whose professions are either illegitimate or disreputable, has easily been found in Chinese classical novels. The purpose of this paper is to study the images of these women and their interaction with other different kinds of people in the society. Moreover, this paper will examine the value and the role how they play in the stories. In late Ming Dynasty, romanticism, the bondage of traditional feudalistic thinking and ethical education has been broken down. These women are active and vigorous in the society because they are feminine. They represent the women’s independence in economics. This paper will be divided into six chapters . Chapter One is the Introduction, and “ San Ku Liu Po” is also defined in this chapter. Chapter Two explains the background of late Ming Dynasty and discusses the politics, economics, culture and the contemporary social customs. Chapter Three critically analyzes the images and characteristics of these women and gives examples which are found in those novels. Chapter Four discusses the relationship between “ San Ku Liu Po ” and other different kinds of people. Chapter Five puts emphasis on what roles these women play in each story and their function of matchmaking men and women. Chapter Six is the Conclusion, summarizing all the study of the former five chapters and offering the development of the research in the future.

APA, Harvard, Vancouver, ISO, and other styles

5

Yang, Li-Chung Ou, and 歐陽立中. "The narrative research of "San Yan Er Pai" focusing on the episodes happening within the space of boats." Thesis, 2016. http://ndltd.ncl.edu.tw/handle/63561764001437642780.

Full text

Abstract:

碩士
國立臺灣大學
中國文學研究所
104
The Boat building has a significant influence on human development. With boats, humans are able to travel across different fields and no longer limited by water. In Chinese literature, besides being as a vehicle, boats also contain different imagery and symbols. In classical poems, boats show symbolical meanings of hope, dream, loneliness, freedom, and love. In novels, boats often serve as scenes and involve the change of space. Moreover, human activities on the boat, an enclosed space on the water, help to push stories forward with unexpected twists. “San Yan Er Pai” is an influential collection of vernacular short stories reflecting the public life and social structure in Ming Dynasty. Canals largely established at that time formed an essential transportation for merchants, officials, scholars, and common people. Many scholars have studied “San Yan Er Pai” from different aspects including the story lines, characterization, and cultural affect on the society. While less attention is paid on the relation between the story and boats in the work. Therefore, the main purpose of this paper is to explore the different meanings of boats in “San Yan Er Pai”. This paper will focus on various stories about boat and interpret their influence and significance in the text. Stories related to boat can be divided into three types, and they are respectively about hijacking, romance, and infidelity. Based on different scenarios, the stories are unfolded in the areas of crime, love, and betrayal. To explain the multiple meanings of boats in “San Yan Er Pai”, this paper aims to prove different ideas through the research of texts, cultural background, social order, and human relationships.

APA, Harvard, Vancouver, ISO, and other styles

6

Lai, Mei-shiew, and 賴美雪. "The Research of man styles in the San-Yen Er-Pai." Thesis, 2012. http://ndltd.ncl.edu.tw/handle/86924897475385741137.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Lai, Wen-Hwa, and 賴文華. "The Research in the Your-Mirn in the San-Yen Er-Pai." Thesis, 1996. http://ndltd.ncl.edu.tw/handle/57997768355510506186.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Zheng, Liang-Hong, and 鄭良宏. "The Research on Filial Writing of San Yen, Er Pai and Yi Xing." Thesis, 2016. http://ndltd.ncl.edu.tw/handle/31794986746660074094.

Full text

Abstract:

碩士
國立臺灣大學
中國文學研究所
104
Although there are many different records and discussions about filial from Chinese ancient literaties, they all agree with the important role of piety thoughts on social ethics. And the rapid development of the Ming Dynasty popular literature provides an important artistic medium for the dissemination of filial piety. As the representative of the collection of short stories, San Yen, Er Pai and Yi Xing play important roles in conselling people with stories complied from street stories. Due to the rapid development of commodity economy, the pursuit of secular values, of people living in Ming Dynasty, are stronger than any previous era, which is apparent on the increased proportion of Shisheng Writing in Ming’s Filial Literature. Detailed reading is the important prerequis of this thesis, and the historical and cultural background of literature constitutes an important basis for the analysis, with the life experience of compilers. To sort out Chinese traditional filial piety thoughts is not the purpose of this writing, but to point out the specific performances of the purpose to uphold social ethics in Feng Menglong’s San Yen, Ling Mengchu’s Er Pai and Lu Renlong’s Yi Xing, relying in the traditional mainstream Piety Thoughts. Filial is not just limited to the relationship between Son and Parent, but also could be with Brother, Sister and Son-in-law in the range of family, and with Fellow comrade, Teacher, Servant and King, even though the social and cultural backgrounds of the particular era are likely to affect the social role of Son in play. Therefore, this thesis takes the Father-son Kinship in Five Kinships as the center, then analyze the interactive performances between Filial and Wealth, Lust, Chastity, Friend Kinship, Master-servant relationship and Monarch Relations, including the changes on content and form from the Filial performances based on traditional blood relation in Ming Dynasty cultural context.

APA, Harvard, Vancouver, ISO, and other styles

9

Chen, Kuo-Hsiang, and 陳國香. "The World of Traditional Female Life According to the San Yan Ell Pai I Shyng." Thesis, 1998. http://ndltd.ncl.edu.tw/handle/92193419416509908360.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "(") san yan er pai (")"

1

1580-1644, Ling Mengchu, ed. San yan er pai. Shanghai: Shanghai ci shu chu ban she, 1997.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

2

San yan Er pai yu yan yan jiu. Chengdu Shi: Ba Shu shu she, 2005.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

3

long, Feng meng. San yan er pai he ji. Bei jing: Hua wen chu ban she, 2009.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

4

Menglong, Feng. "San yan""Er pai": Jing shi tong yan. Shanghai: Shanghai da xue chu ban she, 2009.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

5

San yan er pai kan Ming chao. Beijing Shi: Zhonghua shu ju, 2011.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

6

"San yan""Er pai" xu shi yi shu yan jiu. Beijing: Zhongguo she hui ke xue chu ban she, 2010.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

7

"San yan er pai" de jing shen shi yan jiu. [Taibei]: Guo li Taiwan da xue chu ban wei yuan hui, 1994.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

8

Shi jing feng qing: San yan er p'ai di shi jie. Xianggang Jiulong: Zhonghua shu ju, 1988.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

9

Zhang, Zhisen. Pai huai zai cheng shi bian yuan: Er shi shi ji san si shi nian dai Chengdu ren li che fu yan jiu. Wuhan: Hubei ren min chu ban she, 2018.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

10

Cang zai xiang nong li de Ming chao: Cong chang xiao tong su xiao shuo "San yan er pai" kan jie tan xiang yi shu min bai tai. Taibei Shi: Mai tian chu ban, 2012.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Conference papers on the topic "(") san yan er pai (")"

1

Qiu, Shuang, and Ping Yi. "Transmission and Reception of the Translated Versions of San Yan Er Pai in the English World." In 6th International Conference on Humanities and Social Science Research (ICHSSR 2020). Paris, France: Atlantis Press, 2020. http://dx.doi.org/10.2991/assehr.k.200428.099.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Viala, M., M. Alexandre, S. Thézenas, P.-J. Lamy, F. Bibeau, M. Gutowski, P.-E. Colombo, G. Romieu, W. Jacot, and S. Guiu. "Abstract P6-09-28: Prognostic impact of the inclusion of uPA/PAI-1 in ER+/Her2- pN0 early breast cancer adjuvant treatments decision-making." In Abstracts: 2016 San Antonio Breast Cancer Symposium; December 6-10, 2016; San Antonio, Texas. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.sabcs16-p6-09-28.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Ettl, Johannes, Kirsten Große Lackmann, Alexander Hapfelmeier, Evelyn Klein, Stefan Paepke, Christoph Petry, Katja Specht, Laura Wolff, Heinz Höfler, and Marion Kiechle. "Abstract P4-11-27: Prospective comparison of conventional clinicopathological factors, uPA/PAI-1 and EndoPredict®-clin score (EPclin) for adjuvant clinical decision making in ER-positive, HER2-negative breast cancer: Progesterone receptor expression is strongly associat." In Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 9-13, 2014; San Antonio, TX. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.sabcs14-p4-11-27.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!